Immuron Ltd — Regulatory Filings 2011

Jul 20, 2011

==> picture [53 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

==> picture [4 x 35] intentionally omitted <==

Immuron HIV program proceeds to expanded human trial

• Eminent HIV research organisation to expand trialling of Immuron product following initial positive trend in “naive” HIV patients

• NIH to fund expanded testing while Immuron retains full commercialisation rights

• Results presented at IAS Rome provide encouragement

Melbourne, Australia, 21 July 2011: Melbourne biopharmaceutical and development company Immuron Limited (ASX: IMC ) has been ad v ised by its HI V research partner, Case W estern Rese r ve Uni v ersity Center for AIDS Res e arch, Ohio t h at Immuron’ s immune ther a py product, IMM-243, will soon proceed to an ex p anded study o f recently inf e cted (naïve) HIV-1 patient s . To date nin e patients ha v e bee n enrolled an d data generated has show n a positive tr e nd, encoura g ing an expan s ion of the tri a l.

The initial finding s from this tria l were presen t ed this week as a poster a t the Internati o nal AIDS So c iety (IAS) conference i n Rome Italy. IMM-243 wa s shown to p o tentially redu c e plasma lev e ls of microbi a l products in HIV-infected perso n s and thereb y reducing im m une activati o n.

The Cleveland-based AIDS Re s earch group, which is one of the world’s most respec t ed HIV research org a nisations is l e d by Prof Michael Lederm a n. The initial t rial and the i m minent expa n sion will als o be funded by the US National Insti t utes of Healt h (NIH).

Earlier this year, I m muron also announced p o sitive in vitro results for its HIV Microbic i de candidate (IM M -252) which is being developed in conjunction with th e University o f Melbourne.

Immuron Chief E x ecutive Offic e r, Mr Joe Bai n i stated: “This second HIV program for m s part of the Immuron develop m ent program dedicated to novel and pr a ctical approa c hes to comb a ting the dea d ly HIV conundrum. W e are encou r aged by the e arly findings, yet believe t h at with furthe r recruitment o f naïv e patients in this study, we will be better placed to appreciate future applications o f this novel ther a py.”

The link to the po s ter presentat i on is:

pa g .ias2011.o r g/abstracts.aspx?ai d =3842

Con tact
Joe Baini – Chief	Executive Offi cer	Rudi Michelso n
+61 3 8637 1107		Monsoon Communicat ions
joe@ immuron.com		(03) 9620 333 3
		0411 402 737

About Immuron Limited

Imm u ron is a bioph a rmaceutical c o mpany focuse d on oral immunotherapy using dairy-derive d polyclonal ant i body prod u cts for human s . Immuron is a uniquely posi t ioned biotechnology compan y with a versatil e technology platf o rm capable of generating a w ide range of p r oducts with a h igh safety profile. This high s a fety profile m a kes it possible to complet e pre-clinical studies relativel y quickly and in c reases the pr o spect that the c linical develo p ment of I m muron’s produ c ts will be exp e dited. Immuron’s current pro d ucts and prod u ct candidates target infectious dise a ses of the gas t rointestinal tra c t, chronic dis e ases such as t y pe II diabetes and fatty liver ( NASH), and the prev e ntion of influe n za. Immuron h as one produ c t in the market, Travelan, for u se in preventi n g travellers’ diarr h oea. Imm u ron’s main sci e ntific alliance s are with Had a ssah Medical C enter (Israel) a nd the Univer s ities of Melbourne and M onash (Austr a lia).